Company Description
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.
The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.
It is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.
Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021.
Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 30, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 47 |
| CEO | Amro A. Albanna |
Contact Details
Address: 737 N. Fifth Street, Suite 200 Richmond, Virginia 23219 United States | |
| Phone | 909-488-0844 |
| Website | aditxt.com |
Stock Details
| Ticker Symbol | ADTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $9.00 |
| CIK Code | 0001726711 |
| CUSIP Number | 007025109 |
| ISIN Number | US0070256047 |
| Employer ID | 82-3204328 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Amro A. Albanna | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D. | Co-Founder, Chief Innovation Officer, Secretary and Director |
| Thomas J. Farley CPA | Chief Financial Officer |
| Corinne D. Pankovcin CPA, M.B.A. | Chief Commercialization Officer |
| Rowena Albanna | Chief Operating Officer |
| Jennifer Lee | Director of Human Resources |
| Dr. Dolly B. Tyan Ph.D. | Senior Vice President of Clinical Development ? Transplantation |
| Ge Chen M.D., M.S. | Senior Vice President of Preclinical Research and Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 12, 2024 | 8-K | Current Report |
| Apr 4, 2024 | 8-K | Current Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 4, 2024 | 425 | Filing |
| Mar 4, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 8-K | Current Report |
| Feb 29, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K/A | [Amend] Current report |